Babesia microti IgM & IgG Antibodies (IFA) Test
The Babesia microti IgM & IgG IFA test detects class-specific antibodies to the babesiosis protozoan by indirect immunofluorescence, reported as endpoint titres. IgM indicates recent or active exposure and IgG indicates established or past infection, with seroconversion across paired sera most informative.
2
Biomarkers
Blood (serum)
Sample
Approximately 5–10 business days
Turnaround
No
Fasting
What is the B. microti IFA test?
The Babesia microti IgM & IgG Antibodies (IFA) Test measures class-specific antibodies to the intra-erythrocytic protozoan that causes most human babesiosis in North America. By reporting IgM and IgG separately as immunofluorescence endpoint titres, it helps a clinician place a patient along the timeline of infection: IgM points toward recent or active exposure, while IgG reflects an established or past response. It is ordered when tick-borne babesiosis is suspected on clinical and epidemiological grounds — a febrile, often haemolytic illness in someone with exposure to Ixodes-endemic regions — and when serological confirmation of exposure is wanted alongside, not instead of, direct parasite detection.
In the diagnostic landscape, serology occupies a supporting role. Active babesiosis is established by demonstrating the parasite directly: intra-erythrocytic ring forms or the pathognomonic tetrad on a Giemsa-stained thin film, or Babesia DNA by PCR. Antibody testing complements these by documenting the host response, supporting a diagnosis when parasitaemia is low or intermittent, and characterising exposure in the context of suspected co-infection. Because B. microti is transmitted by the same Ixodes scapularis vector as Borrelia burgdorferi and Anaplasma, practitioners frequently order this serology within a broader tick-borne panel, interpreting a reactive result in the light of smear, PCR, and the patient's clinical trajectory rather than as a stand-alone verdict on active infection.
What does the B. microti IFA test measure?
Indirect immunofluorescence uses Babesia microti-infected erythrocytes fixed to a slide as antigen; patient serum is layered on, and bound human IgM is visualised with a fluorescein-labelled anti-IgM conjugate read by a technologist. IgM is the first isotype to appear after infection of red cells by the intra-erythrocytic parasite, typically within the first one to two weeks of symptomatic babesiosis, and generally wanes over weeks to a few months. Because the read-out is a visually scored endpoint dilution rather than a quantified concentration, inter-observer and inter-laboratory variation is inherent to the method.
A reactive IgM titre supports recent exposure to B. microti and, in a symptomatic patient with a compatible exposure history, raises the probability of acute babesiosis. IgM is interpreted with IgG and, critically, with a direct test of parasitaemia — thin-film blood smear or PCR — because serology reflects the immune response rather than the presence of live parasites. IgM can persist or reappear and is prone to cross-reaction, so a positive IgM alone does not confirm active infection.
IgG against B. microti is detected by the same slide-based immunofluorescence method using an anti-IgG conjugate. Class-switched IgG becomes detectable roughly two to four weeks after infection, peaks during convalescence, and can remain measurable for a year or more after the parasite has been cleared. A rising titre across acute and convalescent sera (classically a four-fold change) is more informative than a single value, because a stable low-level IgG may represent remote, resolved exposure.
IgG distinguishes established or past infection from the earliest acute phase. A high or rising IgG titre supports recent B. microti infection, whereas a stable low titre is more consistent with prior exposure in an endemic region. Because IgG can persist long after clearance, it cannot by itself establish active disease; it is read alongside IgM, smear, and PCR, and is most useful when paired acute and convalescent specimens demonstrate seroconversion.
Why is the B. microti IFA test ordered?
- Clinicians evaluating a patient with unexplained fever, chills, fatigue, and haemolytic indices (anaemia, raised LDH, low haptoglobin) after possible Ixodes tick exposure in an endemic region
- Practitioners investigating suspected babesiosis when thin-film smear is negative or equivocal and additional evidence of exposure is sought alongside PCR
- Clinicians working up a known or suspected Lyme disease patient for Babesia co-infection, where persistent symptoms suggest more than one tick-borne pathogen
- Transfusion-medicine or haematology practitioners assessing possible transfusion-transmitted babesiosis in a recipient with compatible symptoms
- Physicians monitoring immunocompromised or asplenic patients, in whom babesiosis can be severe and protracted, for serological evidence of exposure
- Clinicians obtaining paired acute and convalescent sera to document seroconversion or a four-fold titre rise when a single sample is inconclusive
- Practitioners assessing a patient with a history of travel or residence in the north-eastern or upper-midwestern United States presenting with a flu-like illness of uncertain cause
- Specialists in persistent or relapsing illness evaluating prior Babesia exposure as part of a structured tick-borne co-infection differential
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
Approximately 5–10 business days
Collection notes
Phlebotomy for a serum specimen. No fasting or special patient preparation is required. Where babesiosis is clinically suspected, a concurrent EDTA whole-blood sample for thin-film smear and/or PCR should be arranged, since serology does not establish active infection on its own. Paired acute and convalescent sera, drawn two to four weeks apart, materially improve interpretation when a single result is equivocal.
Specimen requirements
Serum collected by venepuncture (serum separator tube), separated from cells promptly and transported to the specialty laboratory per its instructions. Cold-chain requirements, minimum volume, and acceptable transit times are set by the performing laboratory and should be confirmed directly, as they differ from routine serum chemistry handling.
What can affect B. microti IFA results?
Serology drawn in the first days of illness may precede detectable IgM and IgG, producing a falsely non-reactive result; repeat or convalescent testing is needed to capture seroconversion.
B. microti IFA can cross-react with antibodies to other Babesia species (such as B. duncani) and, less often, with Plasmodium or Toxoplasma antibodies, raising the apparent titre without indicating B. microti infection.
An impaired humoral response in immunocompromised or asplenic patients can blunt or delay antibody production, so a low or non-reactive titre does not exclude active infection in these groups, where parasitaemia may nonetheless be high.
IgG can remain detectable for months to years after clearance, so a reactive IgG in an endemic-area resident may reflect past exposure rather than current disease and can be misread as evidence of active infection.
Rheumatoid factor, antinuclear antibodies, or non-specific polyclonal stimulation can interfere with immunofluorescence reads, particularly for the IgM fraction, producing low-level reactivity unrelated to Babesia.
Improper serum separation, haemolysis, or delays and temperature excursions during transport to the specialty laboratory can degrade antibody integrity or increase background fluorescence, affecting the scored endpoint titre.
What do B. microti IFA results mean?
Elevated
A reactive IgM with or without IgG, in a symptomatic patient with compatible exposure, supports recent or active B. microti infection and should prompt direct confirmation by thin-film smear and/or PCR. A high or rising IgG, especially a four-fold increase across paired acute and convalescent sera, supports recent infection. Reactive results are interpreted against the clinical picture and direct parasite detection, and cross-reactivity with other Babesia species or protozoa is considered when the epidemiology does not fit.
Normal
A non-reactive result (both isotypes below the laboratory cut-off) is the expected finding in individuals without exposure. In an endemic area, a non-reactive IgG makes remote past infection unlikely. Serostatus describes the antibody response only; it neither confirms nor excludes current parasitaemia, which requires a direct test.
Reduced
Non-reactive IgM and IgG in an unexposed, immunocompetent person argues against babesiosis but does not exclude very early infection sampled before seroconversion or infection in an immunosuppressed or asplenic patient with a blunted antibody response. When clinical suspicion is high, repeat serology and, more importantly, direct smear and PCR are indicated regardless of a non-reactive result.
Note: This is an indirect immunofluorescence assay whose endpoint titres are scored visually and are method- and laboratory-specific; cut-offs and titre values are not interchangeable with those from other platforms or laboratories. Serology complements but does not replace blood smear and PCR for diagnosing active babesiosis. IgM may persist or cross-react, and IgG may reflect past exposure, so neither isotype alone establishes active infection. Interpret within a tick-borne co-infection context, particularly where Lyme disease or anaplasmosis coexists.
Frequently asked questions
IgM appears first, within one to two weeks of infection, and marks recent or active exposure, while IgG rises later and persists for months to years, reflecting established or past infection. Reading both together, and ideally across paired acute and convalescent sera, places a patient along the infection timeline.
How to access the B. microti IFA test
The B. microti IFA reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Krause PJ, et al. Diagnosis and management of babesiosis (IDSA guideline-related review). Clin Infect Dis. (2021)
- Vannier E, Krause PJ. Human babesiosis. N Engl J Med. (2012)
- Krause PJ, et al. Comparison of PCR with blood smear and inoculation of small animals for diagnosis of Babesia microti parasitemia. J Clin Microbiol. (1996)
- Centers for Disease Control and Prevention. Babesiosis surveillance case definition and serologic (IFA) interpretation. CDC. (2011)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
infectious disease
Lyme Western Blot (IgG/IgM)
The B. burgdorferi IgG and IgM Western Blot detects band-specific serum antibodies to Borrelia burgdorferi antigens by molecular weight, serving as the confirmatory tier-two assay in the two-tier Lyme disease testing algorithm following a positive or equivocal ELISA screen. IgM Western Blot is the appropriate early marker within the first four weeks of symptom onset;
infectious disease
Babesia IgG ImmunoBlot
The Babesia ImmunoBlot IgG test from IGeneX detects band-specific IgG antibodies against Babesia microti and Babesia duncani antigens in serum using an immunoblot format, providing expanded dual-species tick-borne haemoprotozoan serology beyond the coverage of standard CDC-referenced Babesia IFA testing.
comprehensive panels
CBC with Differential
The Complete Blood Count with Differential quantifies and characterises white blood cells (with 5-part leucocyte differential), red blood cells (with erythrocyte indices including MCV, MCH, MCHC, and RDW), and platelets (with mean platelet volume) from a single EDTA whole blood specimen.